Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects

Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Mosc...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Human vaccines & immunotherapeutics Ročník 18; číslo 5; s. 2060018
Hlavní autori:	Borgonovo, Fabio, Stangalini, Carlo Alberto, Tinelli, Carmine, Mariani, Chiara, Mileto, Davide, Cossu, Maria Vittoria, Abbati, Laura, Bilardo, Lara, Gagliardi, Gloria, Cutrera, Miriam, Pellicciotta, Martina, Armiento, Luciana, Dedivitiis, Gianfranco, Capetti, Amedeo F., Rizzardini, Giuliano
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Taylor & Francis 30.11.2022 Taylor & Francis Group
Predmet:	Aged Antibodies, Viral antibody BNT162 Vaccine Brief Report Coronavirus – Short Report covid-19 COVID-19 - prevention & control decline Humans igg Immunoglobulin G kinetics SARS-CoV-2 spike Vaccination vaccine COVID-19 SARS-CoV-2 vaccine antibody IgG decline kinetics spike
ISSN:	2164-5515, 2164-554X, 2164-554X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Moscati" who had received two doses of the BNT162b2 vaccine were enrolled. The antibody response was assessed by the DiaSorin LIAISON-CLIA S1/S2® IgG solution. Cutoff levels for response (>39 BAU/mL) and neutralizing activity (>208 BAU/mL) were derived from DiaSorin official data. Serology was assessed before and after the first vaccination, and 2 weeks and 6 months after the second vaccination. Anti-S IgG in COVID-19 experienced, baseline IgG producers spiked after the first vaccination to median 5044 BAU/mL and decayed at 6 months to 2467.4 BAU/mL. Anti-S IgG in COVID-19 experienced, baseline IgG non-producers spiked after the second vaccination to median 1701.7 BAU/mL and decayed at 6 months to 904.8 BAU/mL. Anti-S IgG in COVID-19 naïve subjects spiked after the second vaccination to median 546 BAU/mL and decayed at 6 months to 319.8 BAU/mL. The differences between sequential timepoint levels in each group were statistically significant (p < .0001). Serology analysis revealed different kinetics between COVID-19 experienced subjects depending on baseline response, possibly predicting different IgG persistence in blood.
AbstractList	Vaccination toward SARS-CoV-2 reduced mortality and ‘boosters’ are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home “San Giuseppe Moscati” who had received two doses of the BNT162b2 vaccine were enrolled. The antibody response was assessed by the DiaSorin LIAISON-CLIA S1/S2® IgG solution. Cutoff levels for response (>39 BAU/mL) and neutralizing activity (>208 BAU/mL) were derived from DiaSorin official data. Serology was assessed before and after the first vaccination, and 2 weeks and 6 months after the second vaccination. Anti-S IgG in COVID-19 experienced, baseline IgG producers spiked after the first vaccination to median 5044 BAU/mL and decayed at 6 months to 2467.4 BAU/mL. Anti-S IgG in COVID-19 experienced, baseline IgG non-producers spiked after the second vaccination to median 1701.7 BAU/mL and decayed at 6 months to 904.8 BAU/mL. Anti-S IgG in COVID-19 naïve subjects spiked after the second vaccination to median 546 BAU/mL and decayed at 6 months to 319.8 BAU/mL. The differences between sequential timepoint levels in each group were statistically significant (p < .0001). Serology analysis revealed different kinetics between COVID-19 experienced subjects depending on baseline response, possibly predicting different IgG persistence in blood. Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Moscati" who had received two doses of the BNT162b2 vaccine were enrolled. The antibody response was assessed by the DiaSorin LIAISON-CLIA S1/S2® IgG solution. Cutoff levels for response (>39 BAU/mL) and neutralizing activity (>208 BAU/mL) were derived from DiaSorin official data. Serology was assessed before and after the first vaccination, and 2 weeks and 6 months after the second vaccination. Anti-S IgG in COVID-19 experienced, baseline IgG producers spiked after the first vaccination to median 5044 BAU/mL and decayed at 6 months to 2467.4 BAU/mL. Anti-S IgG in COVID-19 experienced, baseline IgG non-producers spiked after the second vaccination to median 1701.7 BAU/mL and decayed at 6 months to 904.8 BAU/mL. Anti-S IgG in COVID-19 naïve subjects spiked after the second vaccination to median 546 BAU/mL and decayed at 6 months to 319.8 BAU/mL. The differences between sequential timepoint levels in each group were statistically significant (p < .0001). Serology analysis revealed different kinetics between COVID-19 experienced subjects depending on baseline response, possibly predicting different IgG persistence in blood.Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Moscati" who had received two doses of the BNT162b2 vaccine were enrolled. The antibody response was assessed by the DiaSorin LIAISON-CLIA S1/S2® IgG solution. Cutoff levels for response (>39 BAU/mL) and neutralizing activity (>208 BAU/mL) were derived from DiaSorin official data. Serology was assessed before and after the first vaccination, and 2 weeks and 6 months after the second vaccination. Anti-S IgG in COVID-19 experienced, baseline IgG producers spiked after the first vaccination to median 5044 BAU/mL and decayed at 6 months to 2467.4 BAU/mL. Anti-S IgG in COVID-19 experienced, baseline IgG non-producers spiked after the second vaccination to median 1701.7 BAU/mL and decayed at 6 months to 904.8 BAU/mL. Anti-S IgG in COVID-19 naïve subjects spiked after the second vaccination to median 546 BAU/mL and decayed at 6 months to 319.8 BAU/mL. The differences between sequential timepoint levels in each group were statistically significant (p < .0001). Serology analysis revealed different kinetics between COVID-19 experienced subjects depending on baseline response, possibly predicting different IgG persistence in blood.
Author	Pellicciotta, Martina Tinelli, Carmine Rizzardini, Giuliano Armiento, Luciana Abbati, Laura Capetti, Amedeo F. Cutrera, Miriam Stangalini, Carlo Alberto Bilardo, Lara Mileto, Davide Mariani, Chiara Borgonovo, Fabio Dedivitiis, Gianfranco Gagliardi, Gloria Cossu, Maria Vittoria
Author_xml	– sequence: 1 givenname: Fabio surname: Borgonovo fullname: Borgonovo, Fabio organization: 1st Division of Infectious Diseases, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 2 givenname: Carlo Alberto surname: Stangalini fullname: Stangalini, Carlo Alberto organization: ’San Giuseppe Moscati’ Foundation, Milano, Italy – sequence: 3 givenname: Carmine surname: Tinelli fullname: Tinelli, Carmine organization: Biometrics and Clinical Statistics Service, Scientific Direction, Fondazione IRCCS Policlinico, Pavia, Italy – sequence: 4 givenname: Chiara surname: Mariani fullname: Mariani, Chiara organization: 1st Division of Infectious Diseases, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 5 givenname: Davide orcidid: 0000-0002-9414-0287 surname: Mileto fullname: Mileto, Davide organization: Clinical Microbiology Unit, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 6 givenname: Maria Vittoria surname: Cossu fullname: Cossu, Maria Vittoria organization: 1st Division of Infectious Diseases, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 7 givenname: Laura surname: Abbati fullname: Abbati, Laura organization: ’San Giuseppe Moscati’ Foundation, Milano, Italy – sequence: 8 givenname: Lara surname: Bilardo fullname: Bilardo, Lara organization: ’San Giuseppe Moscati’ Foundation, Milano, Italy – sequence: 9 givenname: Gloria surname: Gagliardi fullname: Gagliardi, Gloria organization: Clinical Microbiology Unit, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 10 givenname: Miriam surname: Cutrera fullname: Cutrera, Miriam organization: Clinical Microbiology Unit, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 11 givenname: Martina surname: Pellicciotta fullname: Pellicciotta, Martina organization: 1st Division of Infectious Diseases, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 12 givenname: Luciana surname: Armiento fullname: Armiento, Luciana organization: 1st Division of Infectious Diseases, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 13 givenname: Gianfranco surname: Dedivitiis fullname: Dedivitiis, Gianfranco organization: 1st Division of Infectious Diseases, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 14 givenname: Amedeo F. orcidid: 0000-0003-4633-1035 surname: Capetti fullname: Capetti, Amedeo F. organization: 1st Division of Infectious Diseases, ‘Luigi Sacco’ University Hospital, Milano, Italy – sequence: 15 givenname: Giuliano surname: Rizzardini fullname: Rizzardini, Giuliano organization: 1st Division of Infectious Diseases, ‘Luigi Sacco’ University Hospital, Milano, Italy, School of Medicine, University of the Witwatersrand, Johannesburg, South Africa
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35511791$$D View this record in MEDLINE/PubMed
BookMark	eNp9kkFvFCEcxSemxtbaj6Dh6GVaYIAZYmKiW62bNPbQarwRBv7sspmFFtiN_RR-ZWe7u9V6kAOQx_v_3oH3sjoIMUBVvSb4lOAOn1EiGOeEn1JM6bgJjEn3rDra6DXn7MfB453ww-ok5wUeV4spE-JFddiMOmklOap-nYPR9yjpAig6pEPx1-TsmqLp7AJlSKslGmANQ0baFUhIoGUMZZ435o9fb4igPUVrbYwPuvgYkA9IIxPnMZWNZ3L1fXpeE1kH7dcw8u0fCX7eQvIQDFiUV_0CTMmvqudODxlOdudx9e3zp5vJl_ry6mI6-XBZG9a2pZa9o9gxKh3jWPSi7Tva4JZxYiW3mpKWWtoYArY3ohMt5l3Tt9LpBluppWuOq-mWa6NeqNvklzrdq6i9ehBimimdijcDKC4b1jMjbKM1wxZLR21jtSON65zV3ch6v2XdrvolWAOhJD08gT59CX6uZnGtZCdbwZsR8HYHSPFuBbmopc8GhkEHiKusqBCYYMyYGK1v_s56DNn_6Gh4tzWYFHNO4JTx5eFrxmg_KILVpkJqXyG1qZDaVWic5v9M7wP-P_cbhCrGGQ
CitedBy_id	crossref_primary_10_1177_25424823251377732 crossref_primary_10_3390_microorganisms10091809 crossref_primary_10_3389_fimmu_2023_1183983 crossref_primary_10_3390_vaccines10122149
Cites_doi	10.1038/s41577-021-00550-x 10.1038/s41564-021-01051-2 10.1056/NEJMoa2110345 10.1056/NEJMoa2114583 10.1016/S0140-6736(21)00947-8 10.1016/j.jinf.2021.10.026 10.1101/2021.07.01.21259833 10.3390/vaccines9080910 10.1001/jamainternmed.2020.4616 10.1016/S1473-3099(21)00681-2 10.1016/j.jinf.2021.05.023 10.1038/s41591-021-01377-8 10.1016/j.jinf.2021.08.031 10.1093/cid/ciab214 10.1126/science.abj4176
ContentType	Journal Article
Copyright	2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
Copyright_xml	– notice: 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 The Author(s)
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA
DOI	10.1080/21645515.2022.2060018
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
DocumentTitleAlternate	F. BORGONOVO ET AL
EISSN	2164-554X
ExternalDocumentID	oai_doaj_org_article_5934b4c6d3aa40d09f2d3daf13f8fda8 PMC9897653 35511791 10_1080_21645515_2022_2060018
Genre	Journal Article
GroupedDBID	--- 00X 0YH 30N 4.4 53G AALUX AAYXX ABEIZ ABUPF ACGFS ADBBV ADCVX AECIN AENEX AGYJP AIJEM ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS AQTUD ARJSQ BABNJ BAWUL BLEHA BOHLJ CCCUG CITATION DGEBU DIK EBS EMOBN GROUPED_DOAJ H13 HYE KYCEM LJTGL M4Z O9- RPM SV3 TDBHL TFL TFW TTHFI CGR CUY CVF ECM EIF NPM RIG 7X8 5PM
ID	FETCH-LOGICAL-c477t-9bf20f429f4506b67b82307451d95da2172d23c1edbc68670583b79fa30d9a9f3
IEDL.DBID	DOA
ISICitedReferencesCount	4
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000791131800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2164-5515 2164-554X
IngestDate	Mon Nov 10 04:35:56 EST 2025 Tue Nov 04 02:06:34 EST 2025 Thu Oct 02 05:02:22 EDT 2025 Mon Jul 21 05:59:27 EDT 2025 Tue Nov 18 22:15:17 EST 2025 Sat Nov 29 04:02:29 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	COVID-19 SARS-CoV-2 vaccine antibody IgG decline kinetics spike
Language	English
License	This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c477t-9bf20f429f4506b67b82307451d95da2172d23c1edbc68670583b79fa30d9a9f3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0003-4633-1035 0000-0002-9414-0287
OpenAccessLink	https://doaj.org/article/5934b4c6d3aa40d09f2d3daf13f8fda8
PMID	35511791
PQID	2660100446
PQPubID	23479
ParticipantIDs	doaj_primary_oai_doaj_org_article_5934b4c6d3aa40d09f2d3daf13f8fda8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9897653 proquest_miscellaneous_2660100446 pubmed_primary_35511791 crossref_citationtrail_10_1080_21645515_2022_2060018 crossref_primary_10_1080_21645515_2022_2060018
PublicationCentury	2000
PublicationDate	2022-11-30
PublicationDateYYYYMMDD	2022-11-30
PublicationDate_xml	– month: 11 year: 2022 text: 2022-11-30 day: 30
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Human vaccines & immunotherapeutics
PublicationTitleAlternate	Hum Vaccin Immunother
PublicationYear	2022
Publisher	Taylor & Francis Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis – name: Taylor & Francis Group
References	e_1_3_4_4_1 e_1_3_4_3_1 e_1_3_4_2_1 e_1_3_4_9_1 e_1_3_4_8_1 e_1_3_4_7_1 e_1_3_4_20_1 e_1_3_4_6_1 e_1_3_4_5_1 e_1_3_4_12_1 e_1_3_4_13_1 e_1_3_4_10_1 e_1_3_4_11_1 e_1_3_4_16_1 e_1_3_4_17_1 e_1_3_4_14_1 e_1_3_4_15_1 e_1_3_4_18_1 e_1_3_4_19_1
References_xml	– ident: e_1_3_4_2_1 – ident: e_1_3_4_7_1 doi: 10.1038/s41577-021-00550-x – ident: e_1_3_4_12_1 – ident: e_1_3_4_9_1 doi: 10.1038/s41564-021-01051-2 – ident: e_1_3_4_17_1 doi: 10.1056/NEJMoa2110345 – ident: e_1_3_4_19_1 doi: 10.1056/NEJMoa2114583 – ident: e_1_3_4_3_1 – ident: e_1_3_4_6_1 doi: 10.1016/S0140-6736(21)00947-8 – ident: e_1_3_4_15_1 doi: 10.1016/j.jinf.2021.10.026 – ident: e_1_3_4_4_1 doi: 10.1101/2021.07.01.21259833 – ident: e_1_3_4_13_1 doi: 10.3390/vaccines9080910 – ident: e_1_3_4_20_1 doi: 10.1001/jamainternmed.2020.4616 – ident: e_1_3_4_18_1 doi: 10.1016/S1473-3099(21)00681-2 – ident: e_1_3_4_8_1 doi: 10.1016/j.jinf.2021.05.023 – ident: e_1_3_4_11_1 doi: 10.1038/s41591-021-01377-8 – ident: e_1_3_4_14_1 doi: 10.1016/j.jinf.2021.08.031 – ident: e_1_3_4_10_1 doi: 10.1093/cid/ciab214 – ident: e_1_3_4_5_1 – ident: e_1_3_4_16_1 doi: 10.1126/science.abj4176
SSID	ssj0000702466
Score	2.299498
Snippet	Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19... Vaccination toward SARS-CoV-2 reduced mortality and ‘boosters’ are being implemented. We offer scientific contribution about IgG production in the COVID-19...
SourceID	doaj pubmedcentral proquest pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	2060018
SubjectTerms	Aged Antibodies, Viral antibody BNT162 Vaccine Brief Report Coronavirus – Short Report covid-19 COVID-19 - prevention & control decline Humans igg Immunoglobulin G kinetics SARS-CoV-2 spike Vaccination vaccine
Title	Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects
URI	https://www.ncbi.nlm.nih.gov/pubmed/35511791 https://www.proquest.com/docview/2660100446 https://pubmed.ncbi.nlm.nih.gov/PMC9897653 https://doaj.org/article/5934b4c6d3aa40d09f2d3daf13f8fda8
Volume	18
WOSCitedRecordID	wos000791131800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2164-554X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702466 issn: 2164-5515 databaseCode: DOA dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 2164-554X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702466 issn: 2164-5515 databaseCode: TFW dateStart: 20180102 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 2164-554X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702466 issn: 2164-5515 databaseCode: 0YH dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagAokL4k14VEbiGtaOX_GRtpT2siC1oOUUOXZMI5Us2uxW6q_gLzPjZJddhNQLlxwcO7HGnz0z9vgbQt42WjnmA_gmGhAsHcw520iVI9scN04YG1hKNmGm03I2s5-3Un1hTNhADzwIbqKskLX0OgjnJAvMxiKI4CIXsYzBpWu-YPVsOVNpDTage9JBZQH-QA5mgVpf3ynZBMuwCNzDAi9jodIvdxRT4u__l9H5d-zkljI6fkDuj1YkfT_0_iG51XSPyN0hr-T1Y_LrqPHumiILBJ1HCsJrz_jkrKCn3z9SwNzqB73EYKGephThVFMA4_Kix8oH03Oui7qgV877dtgrpG1HHcVcuosl1jn89PX0KOc27xwslvD98Keo2XAnB9qvatzm6Z-QL8cfzg9P8jHzQu6lMcvc1rFgEVRVlIrpWpsaz-OMVDxYFRwmtQqF8LwJtdelNkyVojY2OsGCdTaKp2Svm3fNc0LB-3ZRod8n0PTiDkDhTekwwEUaLzIi12Kv_EhLjtkxLis-speuR6vC0arG0crIu02znwMvx00NDnBMN5WRVjsVANiqEWzVTWDLyJs1IiqYhni24rpmvuorsHNYIt_TGXk2IGTzKzDpkHiPZ8TsYGenL7tvuvYiUX3bEsxFJV78j86_JPdQIANv5Suyt1ysmtfkjr9atv1in9xm307gaWblfppLvwG7Uhgl
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decay+rate+of+antiS1%2FS2+IgG+serum+levels+after+6+months+of+BNT162b2+vaccination+in+a+cohort+of+COVID-19-naive+and+COVID-19-experienced+subjects&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Borgonovo%2C+Fabio&rft.au=Stangalini%2C+Carlo+Alberto&rft.au=Tinelli%2C+Carmine&rft.au=Mariani%2C+Chiara&rft.date=2022-11-30&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=18&rft.issue=5&rft_id=info:doi/10.1080%2F21645515.2022.2060018&rft.externalDBID=n%2Fa&rft.externalDocID=10_1080_21645515_2022_2060018
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon